Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tanja Stevens"'
Autor:
Tanja Stevens, Ludo Lavreys, Tony Vangeneugden, Els De Paepe, Richard M. W. Hoetelmans, Marc Vanstockem, Thomas N. Kakuda, V. Sekar
Publikováno v:
Clinical Pharmacology in Drug Development. 3:346-352
This 2-part, phase 1, open-label, randomized, crossover study (NCT00752310) assessed ritonavir-boosted darunavir bioavailability (oral suspension vs. tablets), and steady-state darunavir pharmacokinetics (suspension). Part 1: 20 healthy adults random
Autor:
Goedele De Smedt, Wim van den Brink, Hilde Vanaken, Richard M. W. Hoetelmans, Thomas N. Kakuda, Monika Schöller-Gyüre, Monika Peeters, Brian Woodfall, Kati Vandermeulen, Tanja Stevens
Publikováno v:
Journal of clinical pharmacology, 48(3), 322-329. Wiley-Blackwell
TMC125 is a nonnucleoside reverse transcriptase inhibitor (NNRTI) with potent in vitro activity against wild-type and NNRTI-resistant HIV-1. TMC125 is an inducer of CYP3A and an inhibitor of CYP2C. This trial evaluated the effect of TMC125 on the pha
Autor:
Thomas N, Kakuda, Vanitha, Sekar, Ludo, Lavreys, Els, De Paepe, Tanja, Stevens, Marc, Vanstockem, Tony, Vangeneugden, Richard M W, Hoetelmans
Publikováno v:
Clinical pharmacology in drug development. 3(5)
This 2-part, phase 1, open-label, randomized, crossover study (NCT00752310) assessed ritonavir-boosted darunavir bioavailability (oral suspension vs. tablets), and steady-state darunavir pharmacokinetics (suspension). Part 1: 20 healthy adults random
Autor:
Sabrina Spinosa-Guzman, Richard M. W. Hoetelmans, Martine De Pauw, Tanja Stevens, Els De Paepe, Vanitha Sekar, Frank Tomaka
Publikováno v:
Clinical pharmacokinetics. 49(5)
The pharmacokinetics of some HIV protease inhibitors are altered in patients with hepatic impairment. The TMC114-C134 study assessed the pharmacokinetics and safety of darunavir/ritonavir 600 mg/100 mg twice daily in HIV-negative subjects with hepati